...
首页> 外文期刊>Pharmacogenomics >Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer
【24h】

Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer

机译:CYP2C19和CYP2D6中间代谢物中的血清氯吡吡甲胺和去甲基Clomipramine水平

获取原文
获取原文并翻译 | 示例
           

摘要

Pharmacogenetics within psychiatry has the potential to aid in the dose and selection of medications. A substantial number of psychiatric medications are metabolized through either of the highly polymorphic drug-metabolizing enzymes CYP2D6 and CYP2C19. Of these, clomipramine is subject to metabolism by both CYP2C19 and CYP2D6, leaving individuals with deficiencies of these drug-metabolizing enzymes at risk of higher concentrations of the parent molecule. Herein, we present the case of a 29-year-old male with diagnoses of depression and obsessive compulsive disorder who had trialed and failed a dozen psychiatric medications, many of which are subject to metabolism by CYP2D6 and/or CYP2C19, and had most recently been taking clomipramine for approximately 2.5 years. Pharmacogenetic testing revealed this patient to be an intermediate metabolizer for both CYP2C19 ((star)1/(star)2) and CYP2D6 ((star)4/(star)41), which resulted in considerably elevated serum trough concentrations of clomipramine and its active metabolite desmethylclomipramine. This case provides a retrospective view of how the knowledge of an individual's pharmacogenetic test results can aid in their clinical care.
机译:精神病学中的药物发生有可能帮助剂量和选择药物。通过高性多态性药物代谢酶CYP2D6和CYP2C19代谢了大量的精神科药物。其中,CYP2C19和CYP2D6的氯甲吡胺受到代谢的影响,将这些药物代谢酶的缺乏的患者存在于父母分子的风险上。在此,我们展示了一名29岁的男性,诊断抑郁症和痴呆的强迫性疾病,患有有十几种精神病药物的抑郁和强迫性疾病,其中许多是CYP2D6和/或CYP2C19的新陈代谢约束,最近一直服用划分氯敏约2.5年。药物发生测试显示该患者是CYP2C19((星)1 /(星)2)和CYP2D6((星)4 /(星)41)的中间代谢物,其导致氯吡胺的血清槽浓度相当升高活性代谢物去甲基clomipramine。本案例提供了对个人药物发生测试结果的知识如何有助于其临床护理的回顾。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号